A distinct inflammatory profile marked by neutrophil activity and cytokine elevation may underline poor biological response ...

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

SAN DIEGO — Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not alter the benefits of mepolizumab on nasal polyp and VAS ...

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

Mepolizumab is the only approved biologic evaluated in patients with an eosinophilic phenotype characterized by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. 1,2 BEC is ...

Mepolizumab (), an interleukin-5 antagonist, is currently approved for use as an add-on maintenance treatment for patients with severe asthma with an eosinophilic phenotype.It is also indicated in ...

Mepolizumab is an interleukin-5 (IL-5) antagonist that works by preventing IL-5 from binding to its receptor on the surface of eosinophils, reducing blood eosinophils to normal levels.

LONDON, March 6, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose dis ...

Mepolizumab is currently being investigated for severe hypereosinophilic syndrome, nasal polyposis and COPD. In the US, Nucala (100mg fixed dose subcutaneous injection of mepolizumab ...

Mepolizumab, sold as Nucala, was not compared fairly against other asthma treatments, raising questions as to whether it has benefits over other drugs already used for the condition, ...

LONDON, Dec. 12, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted ...

March 9, 2009 — The anti-interleukin-5 monoclonal antibody mepolizumab may be helpful in refractory eosinophilic asthma, according to the results of 2 studies reported in the March 5 issue of ...